MedTrace Logo

Hitting the Mark: Introducing State-of-the-art MRI for Precision Radiotherapy of Glioblastoma

NCT06183983 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-06-12

No results posted yet for this study

Summary

The goal of this prospective cohort study is to assess the potential of advanced MRI for improved radiotherapy target delineation in patients diagnosed with glioblastoma. The main questions it aims to answer are:

* How does the coverage of the recurrence volume by a radiotherapy plan based on advanced MRI compare to the coverage by the clinical radiotherapy plan?
* How does the distribution of the dose to organs at risk by a radiotherapy plan based on advanced MRI compare to the distribution by the clinical radiotherapy plan?

Participants will undergo an extended MRI-protocol prior to radiotherapy. This extended MRI-protocol includes the clinical brain tumor imaging protocol plus additional advanced MRI-sequences. Radiation treatment and patient follow-up will occur according to the clinical standard.

Conditions

Interventions

DIAGNOSTIC_TEST

Extended or additional MRI-scan (with contrast) prior to radiotherapy

The MRI-protocol before radiotherapy is extended with 20 minutes. Patients who would not have received an MRI-scan prior to radiotherapy, will get an extra MRI-scan when participating.

Sponsors & Collaborators

Principal Investigators

  • Alejandra Méndez Romero, MD, PhD · Erasmus Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-03
Primary Completion
2025-08-31
Completion
2026-08-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06183983 on ClinicalTrials.gov